Universal Ibogaine Inc.
IBOGF
$0.065
-$0.005-7.14%
| 04/30/2024 | 01/31/2024 | 10/31/2023 | 07/31/2023 | 04/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.73M | 1.65M | 1.24M | 766.90K | 448.80K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.73M | 1.65M | 1.24M | 766.90K | 448.80K |
| Cost of Revenue | 1.24M | 1.17M | 1.01M | 788.00K | 663.30K |
| Gross Profit | 489.40K | 475.20K | 238.00K | -20.90K | -214.30K |
| SG&A Expenses | 842.80K | 823.90K | 1.06M | 1.28M | 1.80M |
| Depreciation & Amortization | 247.50K | 241.60K | 232.50K | 220.60K | 216.20K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.33M | 2.24M | 2.29M | 2.29M | 2.79M |
| Operating Income | -600.80K | -590.30K | -1.05M | -1.53M | -2.34M |
| Income Before Tax | -1.15M | -878.60K | -1.30M | -1.78M | -4.62M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.15 | -0.88 | -1.30 | -1.78 | -4.62 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.15M | -878.60K | -1.30M | -1.78M | -4.62M |
| EBIT | -600.80K | -590.30K | -1.05M | -1.53M | -2.34M |
| EBITDA | -353.40K | -348.70K | -817.60K | -1.31M | -2.12M |
| EPS Basic | -0.01 | 0.00 | -0.01 | -0.01 | -0.02 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | -0.01 | -0.01 |
| EPS Diluted | -0.01 | 0.00 | -0.01 | -0.01 | -0.03 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 859.89M | 766.93M | 766.63M | 765.62M | 764.54M |
| Average Diluted Shares Outstanding | 859.89M | 766.93M | 766.63M | 765.62M | 764.54M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
